News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If it works = $1/share "A methodology that physically removes the pathophysiologic basis of the disease" :)
$HALB has a really nice S/S for a double zero company, especially with all the good news of late. Market cap is sub $3M
https://www.otcmarkets.com/stock/HALB/security
time for HALB after BIEI
THE LOOK AHEAD
Halberd is finalizing the arrangements with Mississippi State University to develop and conduct an animal testing protocol for Halberd's patent-pending nasal spray to safely counteract the effects of Traumatic Brain Injury.
Halberd has the option to consider loans to complete the required audits and the QB up-list. However, Halberd's Articles of Incorporation preclude the issuance of any convertible promissory notes, convertible preferred stock or other convertible instruments. Halberd has chosen to remain as "OTC Markets Pink Sheets" for the near-term.
Halberd is about to embark on a huge previously unannounced expansion of its capability to eradicate multiple antibiotic-resistant bacteria with a single proprietary antibody. While that will require a major focus by Halberd, it offers the largest potential short-term payback to the company and its stockholders.
Halberd's goal has always been to either secure a significant government contract or partner with Big Pharma, because it did not have the huge quantity of funds necessary to secure FDA approval for its products or processes.
Government contracts and Big Pharma are not concerned with a company's stock exchange listing; they are focused on the content of the technology being evaluated. With each accomplishment, Halberd moves closer to finalizing a potential government contract and suitable terms for an agreement with Big Pharma.
Leadership is about making tough decisions using the facts to obtain optimum results. Halberd believes that its interests are best served for the short-term by investing its available resources to advance our technology through R&D and put Halberd in a better position to secure a potential government contract and/or a relationship with Big Pharma.
$HALB Halberd Corporation 2022 Year End CEO Letter and 2023 Goals
https://www.accesswire.com/733750/Halberd-Corporation-2022-Year-End-CEO-Letter-and-2023-Goals
Profound Advancements Explained
JACKSON CENTER, PA / ACCESSWIRE / January 3, 2023 / Halberd Corporation (OTC PINK:HALB) The second half of 2022 was a very busy time.
2022 2nd HALF ACHIEVEMENTS
Halberd's previous research on development of a monoclonal antibody (mAb) against COVID-19 (SARS-COV-2) was found to enhance the effectiveness of the leading commercial COVID antibody by 44.4%.
Halberd formed a Cancer Therapeutics Subsidiary, Halberd Cancer Therapeutics, LTD, to allow cancer treatment research to continue in parallel and synergistically with Halberd's work on the development of treatments for neurodegenerative diseases. Halberd's base extracorporeal technology is flexible enough to treat numerous diseases through tailoring of designed antibodies. The subsidiary's mission is to develop treatments for various types of cancer utilizing the combined patented and patent-pending technology of both Halberd Corporation, and Halberd Cancer Therapeutics, LTD.
Carl Eller, the President of the NFL Retired Player's Association issued an open letter endorsing Halberd's efforts in its research into effective treatments for Traumatic Brain Injury (TBI) and Chronic Traumatic Encephalopathy (CTE), which affects many former and current professional athletes, particularly professional football players.
Halberd was able to demonstrate precise control of a key Cancer related T-Cell protein, PD-1 (programmed cell death-1). PD-1 can be used by tumor cells to fool the body's immune system into allowing the tumor to grow. Precise control of PD-1 levels can allow the body's immune system to attack and eliminate the tumor.
Halberd entered a strategic alliance with AI Longevity, Inc. and Stem of Hope as a wholly owned subsidiary of Halberd Corporation named "ExtendalifeTM." The mission of this subsidiary is to develop treatments intended to increase longevity and develop successful Alzheimer's Disease and Cancer treatments using the combined patented and patent-pending technologies of the alliance member companies.
Halberd's researchers successfully demonstrated the removal of Interleukin-6 (IL-6) from human blood serum during in-vitro laboratory studies. Excess IL-6 is associated with inflammation in rheumatoid arthritis, MS, some cancers and neurodegenerative diseases. Halberd had earlier demonstrated its ability to precisely control the levels of target antigens present in bodily fluid.
Halberd created a single designed monoclonal antibody which has demonstrated the ability to eradicate multiple antibiotic resistant bacteria from buffer solution in the laboratory. The antibody, with a strong affinity to E. coli and similar bacteria, was conjoined to a metallic nanoparticle and exposed to laser emissive energy. The exposed bacteria were eliminated in a matter of minutes.
Halberd's in-vitro laboratory tests successfully demonstrated eradication of five identified cancer disease antigens -- CTLA-4, PD-1, PDL-1, IL-6, and TNF-Alpha -- through the use of laser emissive energy, similar to how antibiotic-resistant bacteria were eliminated.
Halberd reached an agreement with the Hamden Group, a newly formed corporation which consists of members of the Peter Croden family and Darren Hamans. Peter Croden was the former president of Upjohn Corp, Canada, and Upjohn, Europe. Hamden will have worldwide exclusive rights to sell, market and distribute the Halberd patented low dose Naltrexone medication, and the Halberd proprietary Vita-Shield-MaxTM nutraceutical product.
Halberd's COVID research led to the publication of a peer reviewed scientific article titled, "A Novel Plant-Made Monoclonal Antibody Enhances the Synergetic Potency of an Antibody Cocktail Against The SARS-Cov-2 Omicron Variant." The article is available on-line.
Halberd's CEO, William A. Hartman, and CTO, Dr. Mitchell S. Felder, in an October "The Street Reports" podcast, discussed Halberd's groundbreaking accomplishments utilizing its extracorporeal technology in treating major diseases which heretofore had been regarded as incurable. In December, Hartman and Felder again participated in a "The Street Reports" podcast to discuss Halberd's success in eradicating major Cancer disease antigens.
Halberd researchers recently requested and received from the CDC (Centers for Disease Control and Prevention) an array of antibiotic-resistant bacteria (ARB) for testing Halberd's laser eradication technology which had successfully eradicated numerous Gram-Negative bacteria in prior experimentation.
Halberd prepared a Form 15 for filing with the SEC to restore Halberd as a compliant, up-to-date, fully reporting company. This action should lead to the near term removal of the YIELD sign from the HALB stock symbol on the OTC Markets site.
We have engaged with a Congressional Representative from Pennsylvania seeking his support in exposing Halberd's technology for the treatment of Traumatic Brain Injury (TBI) and suicide ideation to various government agencies, such as DARPA (Defense Advanced Research Projects Agency). DARPA has already reviewed preliminary material and has shown interest in receiving additional information. Follow-up will proceed in Q1-2023.
THE LOOK AHEAD
Halberd is finalizing the arrangements with Mississippi State University to develop and conduct an animal testing protocol for Halberd's patent-pending nasal spray to safely counteract the effects of Traumatic Brain Injury.
Halberd has the option to consider loans to complete the required audits and the QB up-list. However, Halberd's Articles of Incorporation preclude the issuance of any convertible promissory notes, convertible preferred stock or other convertible instruments. Halberd has chosen to remain as "OTC Markets Pink Sheets" for the near-term.
Halberd is about to embark on a huge previously unannounced expansion of its capability to eradicate multiple antibiotic-resistant bacteria with a single proprietary antibody. While that will require a major focus by Halberd, it offers the largest potential short-term payback to the company and its stockholders.
Halberd's goal has always been to either secure a significant government contract or partner with Big Pharma, because it did not have the huge quantity of funds necessary to secure FDA approval for its products or processes.
Government contracts and Big Pharma are not concerned with a company's stock exchange listing; they are focused on the content of the technology being evaluated. With each accomplishment, Halberd moves closer to finalizing a potential government contract and suitable terms for an agreement with Big Pharma.
Leadership is about making tough decisions using the facts to obtain optimum results. Halberd believes that its interests are best served for the short-term by investing its available resources to advance our technology through R&D and put Halberd in a better position to secure a potential government contract and/or a relationship with Big Pharma.
SUMMARY
Halberd management has guided the company thus far to achieve technological advancements beyond those of Big Pharma. Halberd's success was demonstrated by way of publication of the peer-reviewed journal article and recent press release concerning Halberd's successful development of a monoclonal antibody (mAb) against Covid and Halberd's single antibody which has been shown effective against multiple antibiotic-resistant bacteria. We believe that our decision to focus on R&D is right for both the short- and long-term interests of the company and its stockholders.
We believe in our mission to create and develop safe and effective treatments against many previously perceived incurable diseases and continue to make progress towards achieving that goal.
We appreciate the efforts of our expanding team of research scientists, and the support of our stockholders. We will continue to maintain transparency and regular communication with our family of interested parties.
Sincerely,
William A. Hartman
Chairman, President & CEO
Making moves to go PS current, big move forward IMO
https://twitter.com/HalberdC/status/1608449917265055745
$HALB watching this one, chart bottomed out and now a gap to fill on the upside at .007 https://schrts.co/vHEiExJG
Time to stock up, before the big news.
$HALB Halberd Receives Several Strains of Antibiotic Resistant Bacteria from CDC to Test Laser Eradication
https://www.accesswire.com/730331/Halberd-Receives-Several-Strains-of-Antibiotic-Resistant-Bacteria-from-CDC-to-Test-Laser-Eradication
Halberd's method shown previously to be effective on multiple strains of antibiotic resistant bacteria to be tested on CDC strains.
JACKSON CENTER, PA / ACCESSWIRE / December 6, 2022 / Halberd Corporation (OTC PINK:HALB) has received from the CDC (Centers for Disease Control and Prevention) an array of antibiotic resistant bacteria (ARB). Halberd will utilize its laser eradication technology which successfully eradicated numerous Gram-Negative bacteria whose results were reported in an October 18, 2022 press release. Gram-negative bacteria (GNB) are characterized by their high resistance to antibiotics.[1]
The CDC provides various strains of antibiotic resistant bacteria to research organizations to encourage development of methods and means of overcoming/neutralizing the bacteria's resistance to known antibiotics or destroying these bacteria without harming the patient.
Dr. Mitchell S. Felder, Halberd's Chief Technology Officer and a board-certified attending neurologist stated, "Our results to date on E. coli, Salmonella and Shigella have been very encouraging and we are excited to commence testing of our patent-pending methodology on these antibiotic resistant strains from the CDC."
William A. Hartman, Chairman, President & CEO of Halberd Corporation, added, "The importance of the fact that the CDC supplied this material to Halberd Corporation cannot be over-emphasized. Halberd's patented technology could be of intense interest to the government, particularly the military, because of our ability to potentially counteract bio-weapons. We regard this responsibility as important to the potential safety and security of the country and to the interests of the company as well."
some plans with CDC.
Groundbreaking!!!
$HALB "The Street Podcast" Features Halberd's "Groundbreaking" Cancer Treatment Approach.
https://www.accesswire.com/730015/the-street-podcast-features-halberds-groundbreaking-cancer-treatment-approach-listen-now
CEO William Hartman and CTO Mitchell Felder report successful application of Halberd's patented methodology for Cancer Antigen Eradication Treatment.
JACKSON CENTER, PA / ACCESSWIRE / December 5, 2022 / Halberd Corporation's (OTC-PINK:HALB) Chairman, President and CEO William A. Hartman and Chief Technology Officer, Dr. Mitchell S. Felder, interviewed on "The Street Reports," discuss their groundbreaking accomplishments, successfully eradicating Cancer disease antigens".
Listen here: https://thestreetreports.com/the-street-podcast-features-halberds-groundbreaking-breast-cancer-antigen-eradication-listen-now-ceo-william-hartman-and-cto-mitchell-felder-discuss/
Dr. Mitchell S. Felder, Halberd's Chief Technology Officer and a board-certified attending neurologist stated, "The control of various cancer antigen levels is an indispensable step in eliminating and preventing cancer. The HALB approach is to control the exact concentration (to the picogram/ml level) of CTLA-4. The goal is to precisely lower CTLA-4 concentration to the exact, perfect level which would allow the cancer to be destroyed by the immune system, yet not cause any deleterious side effects. We have successfully applied this same technique of controlling antigen levels to other diseases with consistent success. So far, we have demonstrated this control in-vitro, and are moving to in-vivo testing in animals, and eventually in humans."
William A. Hartman, Chairman, President & CEO of Halberd Corporation, added, "What differentiates Halberd Corporation's patent protected approach from other applications is our extracorporeal (outside the body) method. We don't inject anything into the patient nor have them ingest drugs. Our process reduces or eliminates the negative side effects of medications. Over 100,000 deaths in the U.S. are the result of drug side-effects1."
(responsible mod: Bill Moynihan/EHRjunkie)
AI
